Wiley, a global leader in research and learning and one of the world's largest publishers, has unveiled the highly anticipated 2024 edition of the Mass Spectra of Designer Drugs. This essential spectral database, widely regarded as a cornerstone for forensic laboratories worldwide, aims to expedite the identification of illicit substances, including novel psychoactive substances (NPS) such as fentanyl variants, synthetic cannabinoids, and more.
Sourced from a comprehensive array of legal and underground literature, the Mass Spectra of Designer Drugs offers forensic professionals access to the latest data on emerging substances. This year's release boasts an impressive compilation of 35,094 mass spectra, representing 26,712 unique chemical entities, alongside detailed information and chemical structures. Notably, the 2024 update introduces over 850 new mass spectra and over 500 new, unique compounds across major categories of interest.
The Mass Spectra of Designer Drugs is designed to be compatible with most major mass spectrometry data systems, facilitating seamless integration into existing laboratory workflows. In a significant advancement, the database is now available as part of a KnowItAll subscription, compatible with Wiley's KnowItAll spectral analysis software. This integration introduces innovative tools tailored to assist in the identification of novel compounds using structure/fragment relationships, enhancing the capabilities of forensic analysts.
As illicit drug manufacturing continues to evolve, Wiley remains committed to providing forensic professionals with cutting-edge tools and resources to combat drug-related crimes effectively. The Mass Spectra of Designer Drugs 2024 stands as a testament to Wiley's dedication to advancing forensic science and supporting global efforts to ensure public safety.
Click here to read the original press release.
